Peter Mohr

872 total citations
21 papers, 644 citations indexed

About

Peter Mohr is a scholar working on Molecular Biology, Cell Biology and Physiology. According to data from OpenAlex, Peter Mohr has authored 21 papers receiving a total of 644 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 4 papers in Cell Biology and 4 papers in Physiology. Recurrent topics in Peter Mohr's work include Peroxisome Proliferator-Activated Receptors (6 papers), Receptor Mechanisms and Signaling (4 papers) and Hemoglobin structure and function (3 papers). Peter Mohr is often cited by papers focused on Peroxisome Proliferator-Activated Receptors (6 papers), Receptor Mechanisms and Signaling (4 papers) and Hemoglobin structure and function (3 papers). Peter Mohr collaborates with scholars based in Switzerland, Germany and United States. Peter Mohr's co-authors include Christoph Tamm, N. WAESPE‐SARCEVIC, K. Gawrońska, Jacek Gawroński, Uwe Grether, Bernd Kuhn, Jörg Benz, Hans Peter Märki, Markus Meyer and Alfred Binggeli and has published in prestigious journals such as Journal of Biological Chemistry, FEBS Letters and Journal of Medicinal Chemistry.

In The Last Decade

Peter Mohr

21 papers receiving 610 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Mohr Switzerland 13 487 192 72 53 50 21 644
Katsutoshi Yamada Japan 11 502 1.0× 311 1.6× 71 1.0× 121 2.3× 75 1.5× 20 1.0k
Carlos Amezcua United States 12 484 1.0× 213 1.1× 68 0.9× 60 1.1× 18 0.4× 14 920
Leonard L. Winneroski United States 14 492 1.0× 399 2.1× 39 0.5× 83 1.6× 27 0.5× 22 901
Efrosini Barbayianni Greece 16 470 1.0× 152 0.8× 21 0.3× 62 1.2× 45 0.9× 25 659
Zhengping Ma United States 14 361 0.7× 138 0.7× 29 0.4× 30 0.6× 42 0.8× 24 627
Kathryn Skorey Canada 17 597 1.2× 193 1.0× 24 0.3× 57 1.1× 66 1.3× 29 892
Steven A. Boyd United States 18 322 0.7× 320 1.7× 18 0.3× 63 1.2× 48 1.0× 34 739
David H. Singleton United States 10 449 0.9× 200 1.0× 29 0.4× 35 0.7× 21 0.4× 12 755
Frank Marguet France 10 352 0.7× 90 0.5× 50 0.7× 123 2.3× 44 0.9× 11 521
Jehan F. Bagli United States 16 442 0.9× 441 2.3× 40 0.6× 161 3.0× 53 1.1× 47 897

Countries citing papers authored by Peter Mohr

Since Specialization
Citations

This map shows the geographic impact of Peter Mohr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Mohr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Mohr more than expected).

Fields of papers citing papers by Peter Mohr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Mohr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Mohr. The network helps show where Peter Mohr may publish in the future.

Co-authorship network of co-authors of Peter Mohr

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Mohr. A scholar is included among the top collaborators of Peter Mohr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Mohr. Peter Mohr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Berking, Carola, Elisabeth Livingstone, Dirk Debus, et al.. (2023). COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma. Cancers. 15(18). 4436–4436. 2 indexed citations
2.
Mohr, Peter, Bernd Kuhn, Hans Peter Maerki, et al.. (2012). Comparative Molecular Profiling of the PPARα/γ Activator Aleglitazar: PPAR Selectivity, Activity and Interaction with Cofactors. ChemMedChem. 7(6). 1101–1111. 37 indexed citations
3.
Davies, Kurtis D., Michael Humphries, Francis X. Sullivan, et al.. (2011). Single-Agent Inhibition of Chk1 Is Antiproliferative in Human Cancer Cell Lines In Vitro and Inhibits Tumor Xenograft Growth In Vivo. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 19(7). 349–363. 22 indexed citations
4.
Grether, Uwe, Werner Klaus, Bernd Kuhn, et al.. (2010). New Insights on the Mechanism of PPAR‐targeted Drugs. ChemMedChem. 5(12). 1973–1976. 11 indexed citations
5.
Grether, Uwe, Agnès Bénardeau, Jörg Benz, et al.. (2009). Design and Biological Evaluation of Novel, Balanced Dual PPARα/γ Agonists. ChemMedChem. 4(6). 951–956. 25 indexed citations
6.
Bénardeau, Agnès, Jörg Benz, Alfred Binggeli, et al.. (2009). Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes. Bioorganic & Medicinal Chemistry Letters. 19(9). 2468–2473. 85 indexed citations
7.
Fettes, Alec, Christian Freichel, Cornelia Hertel, et al.. (2009). 5-Hydroxyindole-2-carboxylic Acid Amides: Novel Histamine-3 Receptor Inverse Agonists for the Treatment of Obesity. Journal of Medicinal Chemistry. 52(13). 3855–3868. 27 indexed citations
8.
Kuhn, Bernd, Hans Hilpert, Jörg Benz, et al.. (2006). Structure-based design of indole propionic acids as novel PPARα/γ co-agonists. Bioorganic & Medicinal Chemistry Letters. 16(15). 4016–4020. 64 indexed citations
9.
Anderson, Julie, et al.. (2005). Medical History in Manchester: Health and Healing in an Industrial City 1750-2005. Research Explorer (The University of Manchester). 3 indexed citations
10.
Amorino, George P., et al.. (2000). Preclinical evaluation of the orally active camptothecin analog, RFS-2000 (9-nitro-20(S)-camptothecin) as a radiation enhancer. International Journal of Radiation Oncology*Biology*Physics. 47(2). 503–509. 13 indexed citations
11.
Schiller, Günter, R. Henne, Peter Mohr, & Volker Peinecke. (1996). Intermittently operated 10-kW alkaline water electrolyzer of advanced technology.. elib (German Aerospace Center). 1 indexed citations
12.
Apfel, Christian, et al.. (1995). Enhancement of HL-60 Differentiation by a New Class of Retinoids with Selective Activity on Retinoid X Receptor. Journal of Biological Chemistry. 270(51). 30765–30772. 71 indexed citations
13.
Mohr, Peter, et al.. (1989). Kinetic resolution of racemic β,γ-epoxy esters with pig liver esterase (PLE, e.c. 3.1.1.1.). Tetrahedron Letters. 30(19). 2513–2516. 37 indexed citations
14.
Mohr, Peter, N. WAESPE‐SARCEVIC, Christoph Tamm, K. Gawrońska, & Jacek Gawroński. (1983). A Study of Stereoselective Hydrolysis of Symmetrical Diesters with Pig Liver Esterase. Helvetica Chimica Acta. 66(8). 2501–2511. 153 indexed citations
15.
16.
Kirstein, D., Frieder W. Scheller, & Peter Mohr. (1980). Mechanism of Inactivation of Glucoseoxidase by Hydrogenperoxide. Acta Biotechnologica. 1(0). 65–66. 3 indexed citations
17.
Scheller, Frieder W., Reinhard Renneberg, Peter Mohr, G.-R. Jänig, & K Ruckpaul. (1976). Peroxidatic activity of liver microsomal cytochrome P‐450. FEBS Letters. 71(2). 309–312. 21 indexed citations
18.
Behlke, Joachim, et al.. (1975). [Molecular and complex-chemical studies on methemoglobin from Chironomus thummi thummi and various isolated fractions].. PubMed. 34(3). 365–89. 1 indexed citations
19.
Mohr, Peter, et al.. (1967). Ligand‐Protein Interactions in Imidazole and 1,2,4‐Triazole Complexes of Methaemoglobin from Chironomus plumosus. European Journal of Biochemistry. 3(2). 158–163. 26 indexed citations
20.
Mohr, Peter, et al.. (1967). Untersuchungen zur Natur der Bindung von Pyridinbasen an Hämin in wäßriger Lösung. Zeitschrift für Chemie. 7(8). 303–303. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katsutoshi Yamada Breakdown of academic impact, for papers by Carlos Amezcua Breakdown of academic impact, for papers by Leonard L. Winneroski Breakdown of academic impact, for papers by Efrosini Barbayianni Breakdown of academic impact, for papers by Zhengping Ma Breakdown of academic impact, for papers by Kathryn Skorey Breakdown of academic impact, for papers by Steven A. Boyd Breakdown of academic impact, for papers by David H. Singleton Breakdown of academic impact, for papers by Frank Marguet Breakdown of academic impact, for papers by Jehan F. Bagli
Rankless by CCL
2026